Basal-like breast cancer: a critical review.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Journal of Clinical Oncology

• Publication date

  2008-05-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2007.13.1748PMID 18487574
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• P-cadherin expression is associated with high-grade ductal carcinoma in situ of the breast

  2014cited by this paper
• Predicting protein-protein interactions in Arabidopsis thaliana through integration of orthology, gene ontology and co-expression

  2009influential reference
• Identification of a basal-like subtype of breast ductal carcinoma in situ.

  2007cited by this paper
• The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes

  2007cited by this paper
• The erbB2+ cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial.

  2007influential reference
• BRCA1 dysfunction in sporadic basal-like breast cancer

  2007cited by this paper
• Images in clinical medicine. Rapid progression of basal-type breast cancer.

  2007cited by this paper
• Caveolin 1 Is Overexpressed and Amplified in a Subset of Basal-like and Metaplastic Breast Carcinomas: A Morphologic, Ultrastructural, Immunohistochemical, and In situ Hybridization Analysis

  2007cited by this paper
• Sporadic Invasive Breast Carcinomas With Medullary Features Display a Basal-like Phenotype: An Immunohistochemical and Gene Amplification Study

  2007cited by this paper
• Prognostic markers in triple‐negative breast cancer

  2007cited by this paper
• A mouse model of basal‐like breast carcinoma with metaplastic elements

  2007cited by this paper
• Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers

  2007cited by this paper
• Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity

  2007cited by this paper
• BRCA1, a potential predictive biomarker in the treatment of breast cancer.

  2007cited by this paper
• TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer

  2007cited by this paper
• Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival

  2007cited by this paper
• Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype.

  2007cited by this paper
• Protein Expression Profiling in High-Risk Breast Cancer Patients Treated with High-Dose or Conventional Dose–Dense Chemotherapy

  2007cited by this paper
• Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection.

  2007cited by this paper
• Predominance of the basal type and HER-2/neu type in brain metastasis from breast cancer

  2007cited by this paper
• Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer

  2007cited by this paper
• Nestin is expressed in the basal/myoepithelial layer of the mammary gland and is a selective marker of basal epithelial breast tumors.

  2007cited by this paper
• Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression

  2007cited by this paper
• Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro

  2007cited by this paper
• Deconstructing the molecular portrait of basal-like breast cancer.

  2006cited by this paper
• Basal-like breast carcinomas: clinical outcome and response to chemotherapy

  2006cited by this paper
• EGFR amplification and lack of activating mutations in metaplastic breast carcinomas

  2006cited by this paper
• Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance.

  2006influential reference
• Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer

  2006cited by this paper
• Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue

  2006cited by this paper
• Metaplastic breast carcinomas are basal‐like tumours

  2006cited by this paper
• Linkage between EGFR family receptors and nuclear factor kappaB (NF‐κB) signaling in breast cancer

  2006cited by this paper
• Epidermal growth factor receptor targeting in cancer.

  2006cited by this paper
• Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms

  2006cited by this paper
• Relationship between nuclear grade of ductal carcinoma in situ and cell origin markers.

  2006cited by this paper
• Prognostic Relevance of Basal Cytokeratin Expression in Operable Breast Cancer

  2006cited by this paper
• Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer.

  2006cited by this paper
• Basoluminal Carcinoma: A New Biologically and Prognostically Distinct Entity Between Basal and Luminal Breast Cancer

  2006cited by this paper
• Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients

  2006influential reference
• Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.

  2006cited by this paper
• Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer

  2006influential reference
• Multiple functions of the integrin alpha6beta4 in epidermal homeostasis and tumorigenesis.

  2006cited by this paper
• Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile

  2006cited by this paper
• Novel patterns of genome rearrangement and their association with survival in breast cancer.

  2006cited by this paper
• Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay

  2006cited by this paper
• Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma

  2006cited by this paper
• Breast Cancers With Brain Metastases are More Likely to be Estrogen Receptor Negative, Express the Basal Cytokeratin CK5/6, and Overexpress HER2 or EGFR

  2006cited by this paper
• Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast

  2006cited by this paper
• A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.

  2006cited by this paper
• Basal-like breast cancer and the BRCA1 phenotype

  2006cited by this paper
• Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis.

  2006cited by this paper
• X chromosomal abnormalities in basal-like human breast cancer.

  2006cited by this paper
• Genomic and transcriptional aberrations linked to breast cancer pathophysiologies.

  2006cited by this paper
• Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.

  2006influential reference
• Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas

  2006cited by this paper
• Multiple Functions of the Integrin α6β4 in Epidermal Homeostasis and Tumorigenesis

  2006cited by this paper
• Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene‐expression subtypes of breast cancer

  2006cited by this paper
• Prognostic Significance of Basal-Like Phenotype and Fascin Expression in Node-Negative Invasive Breast Carcinomas

  2006cited by this paper
• Concordance among gene-expression-based predictors for breast cancer.

  2006cited by this paper
• PARP-1 inhibitors: are they the long-sought genetically specific drugs for BRCA1/2-associated breast cancers?

  2006cited by this paper
• Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation

  2006influential reference
• A Basal Epithelial Phenotype Is More Frequent in Interval Breast Cancers Compared with Screen Detected Tumors

  2005cited by this paper
• Immunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma--relation with grade, stage, estrogen receptor and HER2.

  2005cited by this paper
• p63 correlates with both BRCA1 and cytokeratin 5 in invasive breast carcinomas: further evidence for the pathogenesis of the basal phenotype of breast cancer

  2005cited by this paper
• p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas

  2005influential reference
• Typical medullary breast carcinomas have a basal/myoepithelial phenotype

  2005cited by this paper
• Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors

  2005influential reference
• Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy

  2005cited by this paper
• Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype

  2005cited by this paper
• AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer.

  2005cited by this paper
• The prognostic implication of the basal-like (cyclin Ehigh/ p27low/p53+glomeruloid-microvascular-proliferation +) phenotype of BRCA1-related breast cancer

  2005cited by this paper
• Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer

  2005cited by this paper
• Depletion of BRCA1 impairs differentiation but enhances proliferation of mammary epithelial cells.

  2005cited by this paper
• Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization.

  2005cited by this paper
• High‐throughput protein expression analysis using tissue microarray technology of a large well‐characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses

  2005cited by this paper
• Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival.

  2005cited by this paper
• Targeting the DNA repair defect of BRCA tumours.

  2005cited by this paper
• BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles

  2005cited by this paper
• Placental Cadherin and the Basal Epithelial Phenotype of BRCA1-Related Breast Cancer

  2005cited by this paper
• Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

  2005cited by this paper
• Different gene expression patterns in invasive lobular and ductal carcinomas of the breast.

  2004cited by this paper
• KIT (CD117)-positive breast cancers are infrequent and lack KIT gene mutations.

  2004cited by this paper
• Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma

  2004influential reference
• Loss of Heterozygosity and Its Correlation with Expression Profiles in Subclasses of Invasive Breast Cancers

  2004cited by this paper
• Molecular Cytogenetic Identification of Subgroups of Grade III Invasive Ductal Breast Carcinomas with Different Clinical Outcomes

  2004cited by this paper
• The role of BRCA1 in the cellular response to chemotherapy.

  2004cited by this paper
• Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer.

  2004cited by this paper
• Basal and luminal breast cancers: basic or luminous? (review).

  2004cited by this paper
• Array Comparative Genomic Hybridization Analysis of Genomic Alterations in Breast Cancer Subtypes

  2004cited by this paper
• BRCA1 functions as a breast stem cell regulator

  2004cited by this paper
• Hallmarks of 'BRCAness' in sporadic cancers

  2004cited by this paper
• The Prognostic Implication of the Basal-Like (Cyclin Ehigh/p27low/p53+/Glomeruloid-Microvascular-Proliferation+) Phenotype of BRCA1-Related Breast Cancer

  2004cited by this paper
• Expression of luminal and basal cytokeratins in human breast carcinoma

  2004cited by this paper
• Identification and validation of an ERBB2 gene expression signature in breast cancers

  2004cited by this paper
• Different proliferative activity of the glandular and myoepithelial lineages in benign proliferative and early malignant breast diseases

  2004cited by this paper
• The Catalog of Human Cytokeratins: Patterns of Expression in Normal Epithelia, Tumors and Cultured Cells Review

  2004cited by this paper
• Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer

  2004cited by this paper
• Cancer genes and the pathways they control

  2004cited by this paper
• Repeated observation of breast tumor subtypes in independent gene expression data sets

  2003cited by this paper
• Targeting the TGFβ signaling network in human neoplasia

  2003cited by this paper

• Advances in Artificial Intelligence in Prostate Cancer Pathology

  2026cites this paper
• CLINICAL RELEVANCE OF HORMONAL RECEPTOR EXPRESSION IN BREAST CANCER: AN IMMUNOHISTOCHEMICAL STUDY FROM TRIPOLI, LIBYA.

  2025cites this paper
• Melanotransferrin as a Potential Target for the Selective Killing of Melanoma and Triple-Negative Breast Cancer Cells In Vitro Using Novel SNAP-Tag-Based Antibody–AURIF Conjugate

  2025cites this paper
• The Cytochrome CYP4 in Breast and Other Cancers

  2025cites this paper
• Multimodal diagnostic models and subtype analysis for neoadjuvant therapy in breast cancer

  2025cites this paper
• Imaging findings with clinicopathological correlation in breast carcinoma in young women

  2025cites this paper
• BRCA1: An Unrecognized Modulator of Lineage Plasticity in Basal-like Breast Cancer

  2025cites this paper
• Metabolomics Biomarkers for Breast Cancer: An updated perspective.

  2025cites this paper
• Identification of Epigenetic Regulatory Networks of Gene Methylation–miRNA–Transcription Factor Feed-Forward Loops in Basal-like Breast Cancer

  2025cites this paper
• Role of PARP Inhibitors: A New Hope for Breast Cancer Therapy

  2025cites this paper
• Human Cytomegalovirus Infection and Breast Cancer: A Literature Review of Clinical and Experimental Data

  2025cites this paper
• Assessing the Tumor Suppressive Impact and Regulatory Mechanisms of SPDEF Expression in Breast Cancer

  2025cites this paper
• Mitochondrial-Targeting Zwitterionic Nanomedicine Based on Tertiary Amine N-oxide Polymers for Triple-Negative Breast Cancer Therapy.

  2025cites this paper
• Recent Developments in Vesicular Nanocarriers for Targeted Drug Delivery in Breast Cancer.

  2025cites this paper
• Clinical Implications of Breast Cancer Intrinsic Subtypes.

  2025cites this paper
• CXCR4/CXCL12 blockade therapy; a new horizon in TNBC therapy

  2025cites this paper
• Esophageal adenocarcinoma relapse after chemoradiation is dominated by a basal-like subtype

  2025cites this paper
• Exploring ID4 as a driver of aggression and a therapeutic target in triple-negative breast cancer

  2025cites this paper
• Knockdown of PVT1 inhibits cell proliferation in luminal and basal-like breast cancer subtypes by activating LATS2/Hippo signaling pathway

  2025cites this paper
• Subtype-specific HER3 enrichment in basal-like breast cancer is regulated via the GATA2/GATA3-FOXA1 axis.

  2025cites this paper
• Investigation of anti-cancer efficiency of DZNep and Stauprimide combination in breast cancer

  2025cites this paper
• Optimizing the Cell Number and Size for Tumor Spheroid Modeling Using Amyloid Hydrogel

  2025cites this paper
• Neoadjuvant vs. Adjuvant Chemotherapy for Luminal B Breast Cancer: A Systematic Review and Meta-Analysis – Where is the Evidence?

  2025cites this paper
• The TGFβ2‐Snail1‐miRNATGFβ2 Circuitry is Critical for the Development of Aggressive Functions in Breast Cancer

  2024cites this paper
• Exploring the Usefulness of Tumor Budding as a Histopathological Marker Compared to Tumor-Node-Metastasis (TNM) Staging in Breast Cancer

  2024cites this paper
• Subtype Transdifferentiation in Human Cancer: The Power of Tissue Plasticity in Tumor Progression

  2024cites this paper
• Prognostic Value of “Basal-like” Morphology, Tumor-Infiltrating Lymphocytes and Multi-MAGE-A Expression in Triple-Negative Breast Cancer

  2024cites this paper
• C-terminally phosphorylated p27 activates self-renewal driver genes to program cancer stem cell expansion, mammary hyperplasia and cancer

  2024cites this paper
• Breast Cancer Stem Cells Upregulate IRF6 in Stromal Fibroblasts to Induce Stromagenesis

  2024cites this paper
• ASCT2 Regulates Fatty Acid Metabolism to Trigger Glutamine Addiction in Basal-like Breast Cancer

  2024cites this paper
• Prevalence of basal-like phenotype in triple-negative invasive breast carcinomas and a review of the literature

  2024cites this paper
• Understanding of Endomucin: a Multifaceted Glycoprotein Functionality in Vascular Inflammatory‐Related Diseases, Bone Diseases and Cancers

  2024cites this paper
• Survival Analysis of TNBC Subtype Breast Cancer Based on Clinicopathology at Prof. Dr. I.G.N.G Ngoerah Hospital Denpasar

  2024cites this paper
• A deep learning based holistic diagnosis system for immunohistochemistry interpretation and molecular subtyping

  2024cites this paper
• Detection of KRAS Mutations in Triple-negative Breast Cancers by Polymerase Chain Reaction

  2024cites this paper
• Macrophages: Key Players in the Battle against Triple-Negative Breast Cancer

  2024cites this paper
• Integrated analysis of hub genes and intrinsically disordered regions in triple-negative breast cancer

  2024cites this paper
• Roles of miR-20a-5p in breast cancer based on the clinical and multi-omic (CAMO) cohort and in vitro studies

  2024cites this paper
• A Review on Electronic Health Record Text-Mining for Biomedical Name Entity Recognition in Healthcare Domain

  2023cites this paper
• A genetic mosaic mouse model illuminates the pre-malignant progression of basal-like breast cancer

  2023cites this paper
• A Concise Review of Prodigious Salinomycin and Its Derivatives Effective in Treatment of Breast Cancer: (2012–2022)

  2023cites this paper
• Antitumor effect of a novel humanized MUC1 antibody-drug conjugate on triple-negative breast cancer.

  2023cites this paper
• Increased expression of the immunoproteasome subunits PSMB8 and PSMB9 by cancer cells correlate with better outcomes for triple-negative breast cancers

  2023cites this paper
• A genetic mosaic mouse model illuminates the pre-malignant progression of basal-like breast cancer

  2023cites this paper
• Heterodimeric IL-15 (hetIL-15) reduces circulating tumor cells and metastasis formation improving chemotherapy and surgery in 4T1 mouse model of TNBC

  2023cites this paper
• A Comparison of In Vitro Studies between Cobalt(III) and Copper(II) Complexes with Thiosemicarbazone Ligands to Treat Triple Negative Breast Cancer.

  2023cites this paper
• Mammary Glands of Women, Female Dogs and Female Rats: Similarities and Differences to Be Considered in Breast Cancer Research

  2023cites this paper
• Proteomic Dynamics of Breast Cancer Cell Lines Identifies Potential Therapeutic Protein Targets

  2023cites this paper
• Tumor Microenvironment Can Predict Chemotherapy Response of Patients with Triple-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy

  2023cites this paper
• IMPA2 promotes basal-like breast cancer aggressiveness by a MYC-mediated positive feedback loop.

  2023cites this paper
• XPOT Disruption Suppresses TNBC Growth through Inhibition of Specific tRNA Nuclear Exportation and TTC19 Expression to Induce Cytokinesis Failure

  2023cites this paper
• A Narrative Review of Breastfeeding and Its Correlation With Breast Cancer: Current Understanding and Outcomes

  2023cites this paper
• Genomic characteristics of triple negative apocrine carcinoma: a comparison to triple negative breast cancer

  2023cites this paper
• Facts and prospects of peptide in targeted therapy and immune regulation against triple-negative breast cancer

  2023cites this paper
• Drug repurposing for Basal breast cancer subpopulations using modular network signatures

  2023cites this paper
• Everolimus combined with PD-1 blockade inhibits progression of triple-negative breast cancer.

  2023cites this paper
• FOXD1 is associated with poor outcome and maintains tumor-promoting enhancer–gene programs in basal-like breast cancer

  2023cites this paper
• Progress in immune checkpoint inhibition in early-stage triple-negative breast cancer

  2023cites this paper
• ICAM-1-suPAR-CD11b Axis Is a Novel Therapeutic Target for Metastatic Triple-Negative Breast Cancer

  2023cites this paper
• Anti-proliferative, apoptosis inducing, and antioxidant potential of Callistemon lanceolatus bark extracts: an in vitro and in silico study

  2023cites this paper
• Contrasting roles of different mismatch repair proteins in basal-like breast cancer

  2023cites this paper
• Polo-Like Kinase 1 Regulates Chromosomal Instability and Paclitaxel Resistance in Breast Cancer Cells

  2022cites this paper
• Raloxifene potentiates the effect of gefitinib in triple-negative breast cancer cell lines

  2022cites this paper
• Role of Immunotherapy in the Treatment of Triple-Negative Breast Cancer: A Literature Review

  2022cites this paper
• A Knowledge-Based Discovery Approach Couples Artificial Neural Networks With Weight Engineering to Uncover Immune-Related Processes Underpinning Clinical Traits of Breast Cancer

  2022cites this paper
• Mebendazole Increases Anticancer Activity of Radiotherapy in Radiotherapy-Resistant Triple-Negative Breast Cancer Cells by Enhancing Natural Killer Cell-Mediated Cytotoxicity

  2022cites this paper
• Immunotherapy in triple-negative breast cancer: Insights into tumor immune landscape and therapeutic opportunities

  2022cites this paper
• The Multi-Omic Landscape of Primary Breast Tumors and Their Metastases: Expanding the Efficacy of Actionable Therapeutic Targets

  2022influential citation
• Características clínicas de pacientes con Cáncer de Mama y / o Cáncer de Ovario con mutaciones en los genes BRCA1 y BRCA2 en Córdoba, Argentina

  2022influential citation
• Genetic factors involved in breast cancer

  2022cites this paper
• The obesity-breast cancer link: a multidisciplinary perspective

  2022cites this paper
• Proteomic Dynamics of Breast Cancers Identifies Potential Therapeutic Protein Targets

  2022cites this paper
• Cold atmospheric plasmas target breast cancer stemness via modulating AQP3-19Y mediated AQP3-5K and FOXO1 K48-ubiquitination

  2022cites this paper
• Cytokeratins 5 and 17 maintain an aggressive epithelial state in basal-like breast cancer.

  2022cites this paper
• The crosstalk of the human microbiome in breast and colon cancer: A metabolomics analysis.

  2022cites this paper
• High Expression of CD58 and ALDH1A3 Predicts a Poor Prognosis in Basal-like Breast Cancer

  2022cites this paper
• Cold Atmospheric Plasma Attenuates Breast Cancer Cell Growth Through Regulation of Cell Microenvironment Effectors

  2022cites this paper
• The expression of HOXC10 is correlated with tumor-infiltrating immune cells in basal-like breast cancer and serves as a prognostic biomarker

  2022cites this paper
• The Characteristics of Tumor Microenvironment in Triple Negative Breast Cancer

  2022cites this paper
• MoGCN: A Multi-Omics Integration Method Based on Graph Convolutional Network for Cancer Subtype Analysis

  2022cites this paper
• Visualizing Cytokeratin-14 Levels in Basal-Like Breast Cancer via ImmunoSPECT Imaging.

  2022cites this paper
• A Novel Subset of Triple-Negative Breast Cancers with Unique Histology and Immunohistochemical Expression

  2022cites this paper
• Disruption of RBMS3 suppresses PD-L1 and enhances antitumor immune activities and therapeutic effects of auranofin against triple-negative breast cancer.

  2022cites this paper
• PTEN alterations in sporadic and BRCA1-associated triple negative breast carcinomas.

  2022cites this paper
• Loss of polarity protein Par3 is mediated by transcription factor Sp1 in breast cancer.

  2021cites this paper
• CX-5461 Enhances the Efficacy of APR-246 via Induction of DNA Damage and Replication Stress in Triple-Negative Breast Cancer

  2021cites this paper
• Clinical and Demographic Factors, Treatment Patterns, and Overall Survival Associated With Rare Triple-Negative Breast Carcinomas in the US

  2021cites this paper
• The Anticancer Effects of Flavonoids through miRNAs Modulations in Triple-Negative Breast Cancer

  2021cites this paper
• Advances in Tumor Sampling and Sequencing in Breast Cancer and their Application in Precision Diagnostics and Therapeutics.

  2021cites this paper
• Overview of recent advances in metastatic triple negative breast cancer

  2021cites this paper
• CIP2A Interacts with TopBP1 and Drives Basal-Like Breast Cancer Tumorigenesis

  2021influential citation
• The Unique Biology behind the Early Onset of Breast Cancer

  2021cites this paper
• Does Surgical Margin Width Remain a Challenge for Triple-Negative Breast Cancer? A Retrospective Analysis

  2021cites this paper
• Breast Cancer Adjuvant Radiotherapy in BRCA1/2, TP53, ATM Genes Mutations: Are There Solved Issues?

  2021influential citation
• Long-term PM2.5 exposure before diagnosis is associated with worse outcome in breast cancer

  2021cites this paper
• Recent progress in immunotherapy of breast cancer targeting the human epidermal growth factor receptor 2 (HER2)

  2021cites this paper
• RECENT ADVANCES AND CHALLENGES OF A NOVEL DRUG DELIVERY TECHNOLOGY IN TRIPLE-NEGATIVE BREAST CANCER FOR ONCOLOGICAL APPLICATIONS

  2021influential citation
• Mitotic kinases as drivers of the epithelial-to-mesenchymal transition and as therapeutic targets against breast cancers

  2021cites this paper
• Breast Cancer-Speci fi c Mortality in Small-Sized Tumor with Stage IV Breast Cancer: A Population-Based Study

  2021cites this paper
• The clinicopathological and MRI features of patients with BRCA1/2 mutations in familial breast cancer.

  2021cites this paper